key: cord-0832746-5fdbfzge authors: Frick, Anna E.; Gan, Christiaan T.; Vos, Robin; Schwarz, Stefan; Kraft, Felix; Kifjak, Daria; Neyrinck, Arne P.; Van Raemdonck, Dirk E.; Klepetko, Walter; Jaksch, Peter; Verschuuren, Erik A. M.; Hoetzenecker, Konrad title: Lung transplantation for acute respiratory distress syndrome: A multicenter experience date: 2021-07-24 journal: Am J Transplant DOI: 10.1111/ajt.16759 sha: cc6bf00cbb44a1fcf53dcbdae7af484b14b9d68a doc_id: 832746 cord_uid: 5fdbfzge Acute respiratory distress syndrome (ARDS) is a rapidly progressive lung disease with a high mortality rate. Although lung transplantation (LTx) is a well‐established treatment for a variety of chronic pulmonary diseases, LTx for acute lung failure (due to ARDS) remains controversial. We reviewed posttransplant outcome of ARDS patients from three high‐volume European transplant centers. Demographics and clinical data were collected and analyzed. Viral infection was the main reason for ARDS (n = 7/13, 53.8%). All patients were admitted to ICU and required mechanical ventilation, 11/13 were supported with ECMO at the time of listing. They were granted a median LAS of 76 (IQR 50–85) and waited for a median of 3 days (IQR 1.5–14). Postoperatively, median length of mechanical ventilation was 33 days (IQR 17–52.5), median length of ICU and hospital stay were 39 days (IQR 19.5–58.5) and 54 days (IQR 43.5–127). Prolongation of peripheral postoperative ECMO was required in 7/13 (53.8%) patients with a median duration of 2 days (IQR 2–7). 30‐day mortality was 7.7%, 1 and 5‐year survival rates were calculated as 71.6% and 54.2%, respectively. Given the lack of alternative treatment options, the herein presented results support the concept of offering live‐saving LTx to carefully selected ARDS patients. Acute respiratory distress syndrome (ARDS) is a devastating clinical condition associated with a high mortality. 1 Current treatment strategies for ARDS mainly comprise supportive measures aiming to improve gas exchange and to prevent complications such as sepsis, kidney failure, bleeding, and thromboembolic events. These measures include protective lung ventilation, prone positioning, inhaled nitric oxide, surfactant replacement therapy, glucocorticoids, antiinflammatory agents, and early implementation of extracorporeal membrane oxygenation (ECMO). [2] [3] [4] [5] Lung transplantation (LTx) is an established therapy for patients with end-stage chronic lung diseases. However, for acute lung failure, the evidence for LTx is limited to a few case reports. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] To date, the only larger case series of LTx for ARDS was published in 2014 by a South Korean LTx center. This study included nine patients with a median posttransplant survival of 64 months. The authors concluded that LTx can be considered for a selected group of patients with severe ARDS. 20 In Europe and North America, LTx for acute lung failure is not routinely performed based on an international consensus, which is currently being challenged by the ongoing COVID-19 pandemic. 14 Consequently, selection criteria for offering this treatment to patients remain unclear. We therefore sought to summarize the institutional experience of three European high-volume centers with LTx for ARDS, putting special emphasis on patient selection criteria, perioperative challenges and posttransplant outcome. This retrospective, multicenter cohort study included three PGD scores were calculated according to the latest ISHLT consensus 21 and were assessed retrospectively by chest X-rays and arterial blood gas analyses at the time of admission to the intensive care unit (ICU) 24, 48, and 72 h after LTx. Patients on prolonged postoperative ECMO were classified as PGD3 if chest X-rays showed bilateral infiltrations. In case of clear radiographs, prolonged ECMO patients were classified as "ungradable". All statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software). p ≤ .05 were considered significant. Continuous data are presented as mean plus standard deviation when normally distributed, or median with interquartile range when non-normally distributed. For survival analysis, IBM SPSS Statistics version 26.0 (IBM) and Kaplan-Meier curve was used. In all patients, irreversible lung damage without a reasonable chance to recover was evident. This was defined by at least two failed weaning attempts from ECMO, a lung compliance consistently <20 ml/mbar without a trend for improvement, and clear radiological evidence of extensive parenchymal destruction in all lobes. The consideration for LTx was discussed by a multidisciplinary team involving intensive care physicians, lung transplant physicians, lung transplantation surgeons, anesthesiologists and physiotherapists. In all patients the neurological status was evaluated and when sedation could not be reduced to determine intact neurology, a CT of the brain was performed. The median lung allocation score (LAS) was 76 (IQR 50-85) (LAS > 50 corresponds to a "high LAS" status). The lung allograft score (LAS) which was used for all patients refers to the Eurotransplant LAS score. 22 At the time of listing the mean age was 29.2 (±3.6) years, the youngest patient at the time of All recipients received their lungs from a donation after brain death Table 3 . At the time of LTx, the median time on mechanical ventilation and ECMO support were 46 days (IQR 39-71) and 39 days (IQR 24-54), The most common surgical approach was a clamshell incision Five (38.5%) patients received induction therapy (basiliximab n = 3; antithymocyte globulin [ATG] n = 1; alemtuzumab n = 1) and maintenance immunosuppression was based on a standard triple-regimen The median follow-up time was 536 (IQR 142-1524) days. 1 and 5- year survival rates were calculated as 71.6% and 54.2%, respectively To the best of our knowledge, this is the first large case series describing peri-and postoperative outcomes of LTx for ARDS in the ET region. In total, we could identify 13 transplantations for ARDS in three high-volume centers over a time period of 22 years. Only one patient was lost in the early postoperative period, resulting in a 30-day mortality rate of 7.7%. This procedurerelated mortality is comparable to non-ARDS patients bridged to transplantation with ECLS. 23 Although early outcome was encouraging, 5/13 patients died within 5 years after transplantation. However, when looking into the respective causes of death Pneumonia, n (%) 1 (7.7) Groin infection, n (%) 1 (7.7) in detail, respiratory failure due to infection was the reason for death in three patients, abdominal sepsis leading to multi-organ failure in one patient and antibody-mediated rejection (AMR) in one patient. We therefore believe that this impaired long-term survival is not related to the indication or the perioperative challenges associated with ARDS. Thrombosis of the jugular vein is very common when used for ECMO cannulation. 24 The rate of jugular vein thrombosis was 15% The patients of our case series were all younger than 40 years. Despite this, the chronological age of an ARDS patient should not be a selection criterion; however, the functional reserve and preexisting frailty are important factors, which determine the success of lung transplantation. Currently, there is no objective score or reliable tool to quantify the frailty in LTx candidates and the rehabilitation potential. Therefore, the likelihood of a full recovery is individually assessed by a multidisciplinary team including lung transplantation surgeons, pneumologists, intensive care unit physicians and physiotherapists. Recently, objective measures of frailty, which could be also used in sedated and ventilated patients have been proposed. These include core body muscle area and cross-sectional area of mediastinal fat. [27] [28] [29] Within the last decade, the use of ECMO in ARDS has increased significantly. 18, 30 This technology allows the lungs to recover by reducing the driving pressure on the ventilator. On the other hand, it can also be used to bridge patients to lung transplantation. 3, [6] [7] [8] [31] [32] [33] [34] [35] In such a setting it is important to wean the patients off any sedation and start intensive physiotherapy as soon as possible. In some cases, patients can even be mobilized. This "awake ECMO"-concept is opposed to the traditional view that neuromuscular blockade should be part of the therapy for severe ARDS. Already 2-3 days after initiation of mechanical ventilation, the diaphragm can lose up to 50% of its fibers, 36 which can pose substantial hindrance to posttransplant recovery. It is currently a matter of debate how much time an ARDS lung should be given to recover. Anecdotal reports of patients treated by ECMO > 100 days before their lungs started to recover can be found in the literature. However, such long ECMO runs are associated with a high risk of bleeding, thromboembolic complications, neurological complications, infections, and vascular complications. 37 Therefore, the factor time is essential when discussing LTx for ARDS and there is a window of opportunity for potential candidates, which must not be missed. We find the decision which ARDS patients should be transplanted and when to transplant extremely difficult as the likelihood of lung recovery is sometimes hard to predict. We have learned in post-COVID patients that a considerable number of ARDS patients recover their lung function after several weeks or even months of ECMO. In these patients, we found that repeated CT scans and the trend in lung compliance useful parameters to distinguish between patients who will recover and patients who will not recover. In CT scans the amount of ground glass, which is reversible, opposed by areas of fibrosis has evolved as an important selection criterion. However, additional factors such as bacterial superinfections, parenchymal necrosis, bronchopleural fistula and empyema have to be taken into consideration when patients are referred to the LTx team. In this series, it was evident for all transplanted cases, that the likelihood of lung recovery was minimal. In our series, three patients developed acute kidney failure. Notably, at the time of listing all patients had fully recovered kidney function and eGFR was >40 ml/min in all cases. During the early phase of ECMO oliguria is commonly observed, but often recovers after 48 h. 38, 39 This study shows that LTx for ARDS is complex and the perioperative management is demanding. Similar to non-ARDS patients with ECMO support awaiting LTx, lung implantation is challenging due to adhesions and an impaired coagulation after prolonged ECMO bridging. This results in a higher risk for ischemic-reperfusion injury and primary graft dysfunction. 12 Therefore, some LTx centers have started to liberally prolong a VA ECMO into the early postoperative course. This facilitates a lung protective ventilation strategy and allows a prolonged controlled graft reperfusion. The beneficial effects of this concept have recently been highlighted. 33, 40 In the herein reported patient cohort, a relatively high rate of postoperative complications was recorded. Four (30.7%) patients had to be brought back to the operation room for hemothorax. Bleeding related to severe adhesions has been observed as a common problem in patients transplanted post-COVID ARDS. 12 Our study has several limitations. First, the number of analyzed patients is low. Although data granularity was high, comparative statistical tests or subgroup analysis could not be performed. Currently, a pan-European study on ARDS patients treated by LTx is recruiting patients and we hope that this will result in a larger cohort allowing these analyses. Second, the selection criteria which were used by the three LTx centers of this study are purely experience-based and represent personal views. Future studies are needed to validate these selection criteria. Third, patients referred for but eventually not considered for LTx were not analyzed in detail. These numbers would be needed to gain better insight in the proportion of severe ARDS patients amendable for LTx. Fourth, this is a retrospective analysis with the possibility of miscoded data and missing parameters. Last, the study covers a long time period. As therapies have significantly improved over the years, there is certainly an era effect with improved outcomes in more recent patients. In conclusion, ARDS for lung transplantation is challenging but it can be considered for a selected group of patients with acute lung failure. Further multi-center series are needed to confirm the herein presented results. RV is a senior clinical research fellow of the FWO-Flanders. DVR is supported by the Broere Charitable Foundation. This research did not receive any other specific grants from funding agencies in the public, commercial, or not-for-profit sectors. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. A.E. The data that support the findings of this study are available from the corresponding author upon reasonable request. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination Acute respiratory distress syndrome Extracorporeal Membrane Oxygenation for severe acute respiratory distress syndrome Extracorporeal Membrane Oxygenation for ARDS in adults The acute respiratory distress syndrome Lung transplantation following 107 days of extracorporeal membrane oxygenation Lung transplantation after 125 days on ECMO for severe refractory hypoxemia with no prior lung disease Single lung transplantation for adult respiratory distress syndrome after paraquat poisoning Post-traumatic ARDS-a potential indication for lung transplantation? Double lung transplantation for adult respiratory distress syndrome after recombinant interleukin 2 Emergency lung transplantation after extracorporeal membrane oxygenation Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCRpositive patient Use of Extracorporeal Membrane Oxygenation as a bridge to primary lung transplant: 3 consecutive, successful cases and a review of the literature A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation Lung transplantation for respiratory failure resulting from systemic disease The Toronto Lung Transplant Group. Sequential bilateral lung transplantation for paraquat poisoning. A case report Successful sequential double-lung transplantation for adult respiratory distress syndrome after long-term mechanical ventilation Extracorporeal Membrane Oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome Lung transplantation in adult respiratory distress syndrome Lung transplantation as a therapeutic option in acute respiratory distress syndrome Report of the ISHLT Working Group on primary lung graft dysfunction, part I: definition and grading-A 2016 consensus group statement of the International Society for Heart and Lung Transplantation Lung allocation score: the Eurotransplant model versus the revised US model -a crosssectional study Twenty-year experience with extracorporeal life support as bridge to lung transplantation Incidence of cannulaassociated deep vein thrombosis after veno-venous extracorporeal membrane oxygenation Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: a single center experience in 102 lung transplant patients When to consider lung transplantation for COVID-19 Core muscle size predicts postoperative outcome in lung transplant candidates Analytic morphomics predict outcomes after lung transplantation Relationship among radiological measurements of anterior mediastinal fat and outcomes of lung transplantation in fibrotic patients Extracorporeal membrane oxygenation: a ten-year experience Venovenous Extracorporeal Membrane Oxygenation (ECMO) with a heparin-lock bypass system. An effective addition in the treatment of acute respiratory failure (ARDS) Initial experience with single cannulation for venovenous extracorporeal oxygenation in adults Extracorporeal life support as a bridge to lung transplantation-experience of a highvolume transplant center Ambulatory ECMO as a bridge to lung transplant in a previously well pediatric patient with ARDS Venovenous Extracorporeal Membrane Oxygenation as a bridge to lung transplantation: successful transplantation after 155 days of support Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans Clinical complications during veno-arterial extracorporeal membrane oxigenation in postcardiotomy and non post-cardiotomy shock: still the achille's heel Renal function and survival in 200 patients undergoing ECMO therapy Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology Intraoperative extracorporeal membrane oxygenation and the possibility of postoperative prolongation improve survival in bilateral lung transplantation Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries Lung transplantation for acute respiratory distress syndrome: A multicenter experience